Axsome Therapeutics secures FDA priority review for Alzheimer's drug expansion

Axsome Therapeutics has announced several significant developments in its business and pipeline. The company recently secured a priority review from the FDA for Auvelity, targeting agitation in Alzheimer's patients. This comes alongside strong financial performance, including double-digit revenue growth and a reduced net loss.

The FDA granted priority review for Auvelity's supplemental New Drug Application (sNDA) focused on Alzheimer's-related agitation. A decision is expected by April 30, marking a potential expansion of the drug's use. Meanwhile, the company has already begun launch preparations to ensure readiness if approval is granted.

Prescription volumes for Axsome's existing products have risen sharply. Auvelity and Cymbravo, in particular, have seen increased demand, prompting the company to expand its sales team and improve payer access. Sunosi, another key product, has also continued its growth trajectory.

Financially, Axsome reported a significant drop in net losses compared to the previous year. The firm's current cash reserves are projected to support operations until it reaches cash flow positivity under its existing plan. Beyond Auvelity, the company has added AXS-17 to its pipeline, targeting epilepsy development.

Looking ahead, Axsome plans to initiate multiple Phase III trials and pursue additional regulatory filings. These steps aim to further strengthen its product portfolio and market position.

The FDA's priority review for Auvelity's new indication could open a larger patient market for Axsome Therapeutics. With rising prescriptions, expanded sales efforts, and a stronger financial footing, the company is positioning itself for continued growth. Upcoming clinical trials and regulatory submissions will determine the next phase of its development pipeline.